NasdaqGM:IOVABiotechs
Can Iovance Biotherapeutics Recent Rebound Signal Long Term Value After 68.2% Slide in 2025
Wondering if Iovance Biotherapeutics is a beaten down biotech bargain or a value trap? You are not alone, and this deep dive will help you decide whether the current price really makes sense.
The stock has bounced recently, up 12.7% over the last week and 10.7% over the past month, but that recovery still sits against a tough backdrop of a -68.2% year to date return and -95.0% over five years.
Those moves have come as investors refocus on Iovance's pipeline progress and regulatory...